Dr. Rickels conducts patient-oriented diabetes research that aims at understanding the pathogenesis of various forms of diabetes and the in vivo mechanisms of new diabetes treatments, and is in particular focused on islet function and replacement in type 1 diabetes and pancreatogenic forms of diabetes. Dr. Rickels' studies involve methodologies for quantifying insulin and incretin secretion, insulin sensitivity, and glucose counterregulatory responses to hypoglycemia, and include oral glucose and mixed-meal tolerance tests, the frequently-sampled intravenous glucose tolerance test, the glucose-potentiated arginine test, and hyperinsulinemic euglycemic and hypoglycemic clamps. Present work in type 1 diabetes is focused on understanding the mechanisms of defective glucose counterregulation and novel approaches to the prevention or correction of hypoglycemia, including by beta-cell replacement (islet transplantation) therapy or artificial pancreas (closed-loop) technology. Present work in cystic fibrosis-related diabetes is directed at understanding the pathophysiologic defects involved in the etiology of early defects in insulin secretion and the impact of different strategies for enhancing incretin effects on beta-cell function.
Dr. Rickels specializes in the diagnosis and treatment of diabetes, hypoglycemia disorders, and general endocrinologic problems. Dr. Rickels predominantly cares for patients with type 1 and type 2 Diabetes, and is particularly interested in pancreas islet allotransplantation as therapies for type 1 diabetes, as well as islet autotransplantation for patients undergoing total pancreatectomy. Dr. Rickels serves as Medical Director for the Pancreatic Islet Cell Transplantation program at the Hospital of the University of Pennsylvania. Coupled to his research interests in islet function and transplantation as well as closed-loop insulin delivery technology, Dr. Rickels is committed to translating complimentary approaches for cellular and artifical pancreas replacement as treatments for patients with difficult to control type 1 and pancreatogenic diabetes.
Vantyghem MC, de Koning EJP, Pattou F, Rickels MR: Advances in beta-cell replacement therapy for the treatment of type 1 diabetes. Lancet 394(10205): 1274-1285, October 2019.
Rickels MR: Hypoglycemia associated autonomic failure, counterregulatory responses, and therapeutic options in type 1 diabetes. Annals of the New York Academy of Sciences 1454(1): 68-79, October 2019 Notes: Special Issue: Autonomic Nervous System Regulation and Metabolic Diseases.
Rickels MR, Robertson RP: Pancreatic islet transplantation in humans: recent progress and future directions. Endocrine Reviews 40(2): 631-688, April 2019 Notes: Selected for Endocrine Society Thematic Issue on Diabetes.
Kelly A, De Leon DD, Sheikh S, Camburn D, Kubrak C, Peleckis AJ, Stefanovski D, Hadjiliadis D, Rickels MR, Rubenstein RC: Islet hormone and incretin secretion in cystic fibrosis after four months of ivacaftor therapy. American Journal of Respiratory and Critical Care Medicine 199(3): 342-351, February 2019.
Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA, Maahs DM, Tamborlane WV, Bergenstal R, Smith E, Olson BA, Garg SK; T1D Exchange Clinic Network: State of type 1 diabetes management and outcomes from the T1D Exchange in 2016-2018. Diabetes Technology & Therapeutics 21(2): 66-72, February 2019.
Korutla L, Rickels MR, Hu RW, Habertheuer A, Reddy S, Freas A, Harmon J, Korutla V, Ram C, Naji A, Vallabhajosyula P: Noninvasive diagnosis of recurrent autoimmune type 1 diabetes after islet cell transplantation. American Journal of Transplantation 19(6): 1852-1858, June 2019.
Nyirjesy SC,* Sheikh S,* Hadjiliadis D, De Leon DD, Peleckis AJ, Eiel JN, Kubrak C, Stefanovski D, Rubenstein RC, Rickels MR, Kelly A
: Beta-cell secretory defects are present in pancreatic insufficient cystic fibrosis with 1-hour oral glucose tolerance test glucose ≥155 mg/dl. Pediatric Diabetes 19(7): 1173-1182, November 2018 Notes: *Contributed equally as primary authors.
Odorico J, Markmann J, Melton D, Greenstein J, Hwa A, Nostro C, Rezania A, Oberholzer J, Pipeleers D, Yang L, Cowan C, Huangfu D, Egli D, Ben-David U, Vallier L, Grey ST, Tang Q, Roep B, Ricordi C, Naji A, Orlando G, Anderson DG, Poznansky M, Ludwig B, Tomei A, Greiner DL, Graham M, Carpenter M, Migliaccio G, D'Amour K, Hering B, Piemonti L, Berney T, Rickels M, Kay T, Adams A: Report of the Key Opinion Leaders Meeting on Stem Cell-Derived Beta Cells. Transplantation 102(8): 1223-1229, August 2018.
Rickels MR, DuBose SN, Toschi E, Beck RW, Verdejo AS, Wolpert H, Cummins MJ, Newswanger B, Riddell MC; T1D Exchange Mini-Dose Glucagon Exercise Study Group: Mini-dose glucagon as a novel approach to prevent exercise-induced hypoglycemia in type 1 diabetes. Diabetes Care 41(9): 1909-1916, September 2018.
Rickels MR, Peleckis AJ, Dalton-Bakes C, Naji JR, Ran NA, Nguyen H-L, O'Brien S, Chen S, Lee I, Schutta MH: Continuous glucose monitoring for hypoglycemia avoidance and glucose counterregulation in long-standing type 1 diabetes. Journal of Clinical Endocrinology & Metabolism 103(1): 105-114, January 2018 Notes: Editor's Choice.
back to top
Last updated: 07/07/2020
The Trustees of the University of Pennsylvania